Microvascular Therapeutics INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersTucson, AZ
SAM.gov UEIZA54X6LR5AS3
MVT Pharma develops ultrasound contrast agents and theranostic products, including the patented formulation MVT-100, which has completed Phase II clinical trials for echocardiography. The company uses microbubble and nanobubble technologies in its product pipeline, including applications for ultrasound-mediated tumor ablation in brain cancer and sonothrombolysis for conditions including stroke and deep vein thrombosis. MVT-100 is regulated via the FDA 505(b)(1) pathway.
Summarized from the company’s own website
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Microvascular Therapeutics INC | Tucson | AZ | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.